A Phase 3 interventional study of Intravenous topotecan/cisplatin and Intravenous etoposide/cisplatin in Lung Cancer, Small Cell, sponsored by GlaxoSmithKline. Completed at 79 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-03-01.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing topotecan in Small Cell Lung Carcinoma — 2 open to participants now, 4 under way, 2 of them phase 3. Topotecan · Small Cell Lung Carcinoma.
Among the 29 studies testing topotecan in Small Cell Lung Carcinoma, this one is the 3rd largest by enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2002, is one of 7 in phase 3, and was the 17th registered.
1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.
Browse Small Cell Lung Carcinoma studies →2 of the 29 studies testing topotecan in Small Cell Lung Carcinoma are open now, in 12 countries. Recruiting first, the newest first:
Gilead Sciences · Sites in United States, Argentina, Australia and 20 more countries
Ages 18+
Fox Chase Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Topotecan: first FDA approval 1996 (HYCAMTIN), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 14 · Phase 3 7
First in 1995; this study’s year is marked. 2 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 700 is above the median of 56 across 1,077 interventional studies indexed under Small Cell Lung Carcinoma.
Median enrollment 44 across the 28 interventional studies. Of the 22 that completed or were terminated, 3 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 29 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
17 studies in Small Cell Lung Carcinoma by GlaxoSmithKline: 1 open now, 1 under way, 1 of them phase 3. Of 14 finished, 5 (36%) have results posted.
Among the 17 studies in Small Cell Lung Carcinoma by GlaxoSmithKline, this one is the 2nd largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2002, is one of 4 in phase 3, and was the 7th registered.
GlaxoSmithKline’s Small Cell Lung Carcinoma studies by the year they started, since 2000.
2 of the studies testing topotecan in Small Cell Lung Carcinoma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06500026Phase 3Sichuan Baili Pharmaceutical Co., Ltd.A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03) | 2026-12 |
| NCT06449209BioNTech SESafety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 29 studies testing topotecan in Small Cell Lung Carcinoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 17 in Small Cell Lung Carcinoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Evaluation of intravenous Topotecan + Cisplatin as a potential new standard of care in 1st line Small Cell Lung Cancer
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cisplatin 75 mg/m2 i.v., day 1, Etoposide 100 mg/m2 i.v., days 1-3
Drug: Intravenous etoposide/cisplatin
Topotecan 1 mg/ m2, i.v., days 1-5 Cisplatin 75 mg/m2 i.v., days 5
Drug: Intravenous topotecan/cisplatin
Drug pages: Topotecan · Cisplatin
Topotecan 1 mg/m2 should be administered intravenously over a period of 30 minutes on days 1-5. Then a 30 minute saline flush should be administered followed by the cisplatin on day 5. Cisplatin 75 mg/m2 given as an intravenous infusion at the rate of 1 mg/min on day 5 after topotecan.
Cisplatin 75 mg/m2 given as an intravenous infusion at the rate of 1 mg/min on day 1. Cisplatin should be given simultaneously to post-hydration to ensure a high volume fluid. Etoposide 100 mg/m2 should be administered after cisplatin intravenously over a period not less than 30 minutes on days 1 -3.
Median overall survival time of participants
Time frame: Up to 1 year after randomization of the last patient
Number of participants with one year survival rate of the participants
Time frame: Up to 1 year after randomization of the last patient
Median time of disease progression
Time frame: up to 1 year after randomization of the last patient
Median time to event (progressive disease or death) of participants
Time frame: Up to 1 year after randomization of the last patient
Median time to response to chemotherapy
Time frame: Up to 1 year after randomization of the last patient
Median response duration
Time frame: Up to 1 year after randomization of the last patient
Number of participants with objective response
Time frame: Up to 1 year after randomization of the last patient
Mean lung cancer symptom score (LCSS)
Time frame: Up to 18 weeks
Mean eastern cooperative oncology group (ECOG) score
Time frame: Up to 18 weeks
Number of participants with adverse events (AEs) and serious adverse events (SAEs)
Time frame: Up to 1 year after randomization of the last patient
Mean change from Baseline in hemoglobin value
Time frame: Baseline and up to 18 weeks
Mean change from Baseline in leukocytes, neutrophils and platelets count
Time frame: Baseline and up to 18 weeks
Mean change from Baseline in red blood cells (RBCs)
Time frame: Baseline and up to 18 weeks
Mean change from Baseline in Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase and Lactate dehydrogenase (LDH)
Time frame: Baseline and up to 18 weeks
Mean change from Baseline in Blood urea nitrogen (BUN), Potassium, Sodium and urea
Time frame: Baseline and up to 18 weeks
Mean change from Baseline in Creatinine and Total bilirubin
Time frame: Baseline and up to 18 weeks
Mean change from Baseline in Creatinine clearance
Mean change from Baseline in total protein
Time frame: Baseline and up to 18 weeks
Number of participants with abnormal urinalysis results
Mean change from Baseline in weight
Time frame: Baseline and up to 18 weeks
Mean change from Baseline in Body surface area
Time frame: Baseline and up to 18 weeks
The record gives a start of Aug 2002, a primary completion of Feb 2007 and a completion of Feb 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Topotecan · Cisplatin